Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04048850 · ClinicalTrials.gov registry record
Zepatier in Patients with Substance Use
A clinical trial, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- 25
- Enrollment target
NCT04048850 is a clinical trial that has completed, run by University of Illinois at Chicago. The registered enrollment target is 25 participants.
The verdict
NCT04048850 has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
The goal of this study is to assess hepatitis C virus (HCV) treatment with Zepatier (elbasvir/grazoprevir) in HCV monoinfected and human immunodeficiency virus (HIV)-HCV co-infected, HCV treatment-naïve or peginterferon/ribavirin-experienced patients with HCV genotype 1a, without baseline NS5A resistance, 1b, or 4 and substance use in urban, multidisciplinary specialty clinics.
Interventions
- DRUG Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-09-20 |
| Est. Completion | 2022-09-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04048850
The ClinicalTrials.gov registry entry for NCT04048850 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER] is the first listed.
NCT04048850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04048850 about?
NCT04048850 is a clinical study titled "Zepatier in Patients with Substance Use". The goal of this study is to assess hepatitis C virus (HCV) treatment with Zepatier (elbasvir/grazoprevir) in HCV monoinfected and human immunodeficiency virus (HIV)-HCV co-infected, HCV treatment-naïve or peginterferon/ribavirin-experienced patients with HCV genotype 1a, without baseline NS5A resis...
What is the current status of trial NCT04048850?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2019-09-20. Estimated completion is 2022-09-09.
What interventions are being tested in trial NCT04048850?
The interventions under investigation include: Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER] (DRUG).
Who is sponsoring clinical trial NCT04048850?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.